Aortic Aneurysm, Thoracic Clinical Trial
Official title:
Evaluation du Stent Multicouches Dans le Traitement Des anévrismes de l'Aorte Thoraco-abdominale
Evaluation of the Multilayer Flow Modulator (MFM) for Endovascular Thoracoabdominal Aneurysm
Repair.
The objectives of the study is to determine the efficacy, safety and performance of the MFM
and its delivery system in patients at high surgical risk presenting with a type II, III
thoracoabdominal aneurysm, below the left subclavian and above the iliac bifurcation,
according to the Crawford classification.
Conventional treatments of thoracoabdominal aneurysm are medical treatments (based on
hypertension control) on one hand and surgical treatment on the other hand.
The standard treatment is surgery consisting of an exclusion of the aneurysm with
restoration of continuity by means of a prosthesis usually made of Dacron.
- The rates of surgical morbidity and mortality differ according to whether the patient
is treated electively or in an emergency setting. The most feared complication is
spinal cord ischemia inducing paraplegia.
- In elective surgery, operative mortality is estimated to be between 6% and 15%
depending on the series, and around 50% to 60% of patients are treated in an emergency
setting. The rate of neurological complications such as paraparesis or paraplegia is
estimated to be between 3% and 15%.
- In addition to the above, the following major complications have been shown to have an
impact on the morbidity of this major surgery (5% each):
- Bleeding requiring surgical hemostasis
- Respiratory distress syndrome requiring prolonged ventilation support
- Acute renal failure
- Infections
- Central neurological events (stroke and coma)
- Peripheral neurological events (sensory-motor deficits, paraparesis, paraplegia)
Analyses identify risk factors increasing the morbidity and mortality:
- Patients over 80 years
- Chronic obstructive pulmonary disease
- Renal failure
- Coronary artery disease
- Comorbidities (malignancy, etc.)
Compared to surgery, endovascular stenting reduces:
- Pulmonary morbidity (suppression of thoracotomy and ventilation), in patients with
impaired lung function;
- Renal dysfunction;
- Myocardial failure;
- Risk of spinal cord ischemia and paraplegia.
However, this treatment has a number of limitations
- Availability of device in case of emergency
- Topography of the neck must be far enough from the left subclavian artery to allow
satisfactory fixation of the stent and exclusion of the lesion;
- Obstruction of the branches near the aneurysm.
In the current available treatment for this pathology, there are still some disadvantages
such as the difficulty of precise positioning of the prosthesis and its branches which must
cover the aneurysm tissue without endoleaks. Each lesion having anatomical specificities,
the device must be designed for each individual patient, and the operator's technical
ability must be extreme. So, the current technique is difficult to reproduce, and any
emergency treatment is impossible.
The multilayer flow modulator (non-covered) is the device used in this trial The
complications mentioned above are inherent in the concept of covered stent treatment plus
endoleaks that continues to fuel the aneurismal sac untreated, thus subject to the
persistent risk of rupture. With this technique, the visceral arteries are occluded or have
a retrograde flow (which pressurizes the aneurysm again).
The multilayer flow modulator (non-covered) treatment approach avoids the major problems
mentioned above:
- It allows the aneurismal sac to thrombose whilst maintaining the patency of collateral
branches arising from the aneurysm;
- It improves the flow in the collateral branches, which becomes laminar flow through a
mechanism of hemodynamic pressure drop from layer to layer and an increase in speed by
rolling;
- Deployment is easier and it is not different from peripheral stent deployment;
- The device is available in all sizes and all lengths that can be stored, allowing the
management of emergencies.
The space-age 3D geometrical design of a Cardiatis multilayer flow modulator modifies flow
within the aorta in a way that reduces pressure within the aneurysm thus collapsing the
aneurismal sac while preserving any vital collateral circulation.
;
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT02777593 -
Evaluation of the GORE® TBE Device in the Treatment of Lesions of the Aortic Arch and Descending Thoracic Aorta, Zone 2
|
N/A | |
Completed |
NCT02876263 -
Noninvasive Neuromonitoring of Surgery of the Thoracic Aorta
|
N/A | |
Terminated |
NCT02538822 -
Risk of Rupture of Aneurysms of the Thoracic Ascending Aorta (ATA) From the Dynamic Imaging
|
N/A | |
Completed |
NCT04930172 -
TOtal tRansfemoral branCHed endovasCular tHoracoabdominal Aortic Repair Registry
|
||
Completed |
NCT03207568 -
RE-GENERATION: The Safety and Performance of the Relay Pro and Relay NBS Pro Stent-graft Devices in the European Union (EU)
|
N/A | |
Recruiting |
NCT03010514 -
A Registry Study on Genetics and Biomarkers of Thoracic Aortic Aneurysm/Dissection
|
N/A | |
Completed |
NCT02266342 -
GORE® TAG® Thoracic Endoprosthesis French Mandatory Registry
|
||
Completed |
NCT00757003 -
To Evaluate the Safety and Efficacy for GORE TAG Thoracic Endoprosthesis in the Treatment of Thoracic Aortic Disease
|
Phase 3 | |
Recruiting |
NCT03574311 -
Preoperative Intravenous Ferric Carboxymaltose and Placebo in the Treatment of Patients Undergoing Cardiac Surgery
|
Phase 4 | |
Suspended |
NCT03410420 -
Detection of Hypoxia in Human Thoracic Aorta Using Pimonidazole Hydrochloride
|
Phase 1 | |
Recruiting |
NCT05703893 -
Investigation of the Neurovegetative Pattern in Patients With Thoracic Aortic Aneurysms (TAA)
|
||
Enrolling by invitation |
NCT05800743 -
Evaluation of the GORE® Ascending Stent Graft
|
N/A | |
Completed |
NCT02253082 -
Vasculopathic Injury and Plasma as Endothelial Rescue - OCTAplas Trial (EudraCT no. 2014-000452-28)
|
Phase 4 | |
Recruiting |
NCT02323581 -
Endovascular Treatment of TAAA and Aortic Arch Aneurysms Using Fenestrated and Branched Stent Grafts
|
N/A | |
Active, not recruiting |
NCT03414866 -
Thoraflex Hybrid Post-Market Study
|
||
Recruiting |
NCT01985906 -
Safety and Efficacy of Multiple Overlapping Uncovered Stents for Pararenal Aortic Aneurysm Repair
|
N/A | |
Active, not recruiting |
NCT02818972 -
RelayPro Thoracic Stent-Graft in Subjects With Thoracic Aortic Aneurysms and Penetrating Atherosclerotic Ulcers
|
N/A | |
Completed |
NCT03479164 -
Development of Ultra-Low Dose CT Based Screening for Aortic Aneurysms
|
N/A | |
Completed |
NCT01775046 -
Valiant Thoracic Stent Graft With the Captivia Delivery System in the Treatment of Descending Thoracic Aortic Diseases (VALIANT CAPTIVIA France)
|
||
Recruiting |
NCT04814238 -
Minimally Invasive Aortic Root and Aorta surGery rEgistry
|